BrioHealth Reaches 100 BrioVAD Implants, Gains FDA Approval for Pediatric Heart Failure Trial
核心洞察
BrioHealth Solutions (搜索) achieved a significant milestone with the 100th implantation of its investigational BrioVAD System (搜索) across 34 US clinical trial sites since launching in November 2024.
The FDA granted conditional approval for the Brio4Kids Trial, marking the first expansion of the BrioVAD System (搜索) evaluation into pediatric patients with advanced heart failure.
The compact pump design with thin driveline and lightweight components may address critical unmet needs in pediatric heart failure treatment where durable LVAD options remain limited.
BrioHealth Solutions (搜索) has reached a pivotal milestone in mechanical circulatory support with the successful implantation of its 100th investigational BrioVAD System (搜索), while simultaneously securing FDA conditional approval to expand clinical evaluation into pediatric patients with advanced heart failure.
The 100th implant milestone, achieved across 34 US INNOVATE Trial locations since the program's November 2024 launch, demonstrates growing clinical confidence in the device's potential to advance mechanical circulatory support. The BrioVAD System (搜索) is designed as a ventricular assist device (VAD) to support patients with advanced heart failure through next-generation technology focused on performance, reliability, and patient-centered care.
"We're tremendously proud of this milestone and represents our strong alignment with our clinical partners toward advancing the VAD field," said Chen Chen, Ph.D., CEO of BrioHealth Solutions (搜索). "Reaching 100 implants underscores not only the dedication of clinicians and patients participating in the study, but also the real promise of BrioVAD System (搜索)'s design to make life with a mechanical heart device more comfortable and sustainable."
Expanding into Pediatric Population
The FDA's conditional approval for the Brio4Kids Trial represents a significant advancement in addressing unmet medical needs in pediatric heart failure treatment. The study will be conducted under the existing Investigational Device Exemption (IDE) for the INNOVATE Trial, marking an important step toward expanding treatment options for children with advanced heart failure.
Dr. Angela Lorts, Professor of Heart Failure at Cincinnati Children's Hospital Medical Center and a national principal investigator in the study, highlighted the critical need: "In pediatric heart failure, including in school-age children, the lack of durable LVAD options remains a major challenge. This represents a significant unmet need, and we are encouraged to explore the potential of the BrioVAD System (搜索) through the Brio4Kids study."
The BrioVAD System (搜索)'s design features, including its compact pump, thin driveline, and lightweight components, may be particularly suited to meet the unique requirements of pediatric patients, where device size and weight considerations are critical factors in treatment success.
Clinical Progress and Timeline
Francis D. Pagani, M.D., Ph.D., the Otto Gago, M.D., Professor of Cardiac Surgery at University of Michigan Medical School and the INNOVATE Trial's National Principal Investigator, emphasized the clinical significance: "Reaching the 100th BrioVAD System (搜索) implant is a significant milestone for the clinical community and for patients facing advanced heart failure. Each success brings us closer to offering a longer, higher-quality life for individuals who once had few options."
Enrollment in the Brio4Kids US clinical trial is expected to commence in mid-2026, with initial data anticipated in the fourth quarter of 2026. The company continues to expand clinical investigations of the BrioVAD System (搜索) at major cardiac centers across the United States as it works toward commercial approval.
BrioHealth Solutions (搜索), with operations in the United States, China, and Europe, maintains its founding mission of restoring, extending, and enhancing patient lives globally through collaboration with healthcare providers to advance medical technology boundaries. The company's approach extends beyond technology development to include comprehensive clinical training, responsive technical support, and strong hospital partnerships for long-term program development.